Hyderabad, April 4: A ‘Chintan Shivir’ focused on the pharmaceutical sector was held in Telangana’s capital, where senior IAS officer Rajesh Agarwal spoke to the media. He explained that this initiative is part of Prime Minister Narendra Modi’s vision, aimed at bringing together the government, industry, and other stakeholders for in-depth discussions. The goal is to understand the challenges faced by the sector and to outline clear solutions and future directions.
Agarwal emphasized that this platform goes beyond mere discussion. It aims to develop concrete strategies while clarifying the roles of the government, industry, and other relevant parties. This is particularly crucial for the pharma sector, which is a significant and rapidly growing part of India’s economy.
Regarding potential tariffs imposed by the United States on the pharmaceutical sector, Agarwal stated that, according to initial assessments, Indian generic drugs are likely to be exempt from these tariffs. Therefore, the impact on India’s pharma exports is expected to be minimal. However, there could be limited effects on some innovative or patented drugs.
He also mentioned that discussions are ongoing regarding a Trade Framework Agreement between India and the United States. If any segment of the Indian industry faces challenges, these will be addressed under this agreement to find solutions.
Agarwal further noted that India’s pharma sector is in a strong position, with the central government continuously focusing on new markets and products to boost exports. Over the past 5-6 years, India has signed nine Free Trade Agreements (FTAs) covering approximately 38 economies, with a combined economic size exceeding $30 trillion.
According to Agarwal, these agreements will open new opportunities for Indian exporters, diversify markets, and strengthen the domestic industry, thereby creating new job opportunities.
In response to ongoing tensions in the Middle East, he stated that the current crisis is relatively recent, making it difficult to predict long-term effects. However, the government is developing a long-term strategy to address these challenges.
He cited the COVID-19 pandemic as an example of external challenges that arise periodically, noting that India has consistently demonstrated its ability to navigate and progress through such difficulties.
Agarwal asserted that India’s pharma industry, valued at around $60 billion, is now stronger, more modern, and better prepared for global competition than ever before. The government’s goal is for India to take a leading role in emerging sectors such as biosimilars, biologics, and innovative drugs.
He indicated that there are currently no significant signs of a major impact on drug prices. However, if issues arise in the future, the government and industry will work together to find solutions.
He stressed that the top priority at present is to ensure that the supply of medicines remains uninterrupted. The government and industry are collaborating to ensure the availability of medicines both domestically and globally, allowing India’s pharma sector to continue its growth trajectory.
My name is Himanshu Tiwari. I am an experienced content writer with several years of expertise in the field. Currently, I contribute to Daily Kiran, creating engaging and informative content across a variety of categories including TECHNOLOGY, health, travel, education, and automobiles. My goal is to deliver accurate, insightful, and captivating information through my words to help readers stay informed and empowered.
Leave a Comment